Saint Mary's Hospital

ImmunoBrain Checkpoint Appoints Dr. Sanjay Keswani as Chief Executive Officer

Retrieved on: 
월요일, 1월 22, 2024
Bristol Myers Squibb, Neurophysiology, Patient, MD, Sanjay, Medicine, St Bartholomew's Hospital, Johns Hopkins Hospital, Johns Hopkins, Royal College of Physicians, Immunology, Saint Mary's Hospital, Acquisition, Royal college, Bachelor of Science, CMO, IPO, Bartholomew the Apostle, Fibrosis, Hospital, Series A round, FRCP, Roche, Faricimab, Growth, Pharmaceutical industry

NEW YORK, Jan. 22, 2024 /PRNewswire/ -- ImmunoBrain Checkpoint Inc. (ImmunoBrain), a clinical stage biopharmaceutical company developing innovative disease-modifying immune therapies to combat neurodegenerative diseases, today announced the appointment of Dr. Sanjay Keswani, MD, BSc, FRCP, as its President and Chief Executive Officer.

Key Points: 
  • NEW YORK, Jan. 22, 2024 /PRNewswire/ -- ImmunoBrain Checkpoint Inc. (ImmunoBrain), a clinical stage biopharmaceutical company developing innovative disease-modifying immune therapies to combat neurodegenerative diseases, today announced the appointment of Dr. Sanjay Keswani, MD, BSc, FRCP, as its President and Chief Executive Officer.
  • Dr. Keswani is an accomplished physician-scientist with executive leadership experience in both large pharma and small biotech companies.
  • "As a physician-scientist and seasoned biotech executive, Dr. Keswani possesses both the business acumen and the R&D expertise required to serve as Chief Executive Officer of ImmunoBrain," stated Nathan Hevrony, Co-founder and Executive Chairman of ImmunoBrain.
  • I am privileged to work with the ImmunoBrain team and Professor Michal Schwartz whose groundbreaking seminal research has formed the foundation of ImmunoBrain," stated Dr. Sanjay Keswani.

Implantica publishes Interim Report January - September 2023 (Q3)

Retrieved on: 
수요일, 11월 22, 2023
ID, Mary, mother of Jesus, Corporate Affairs, Safety, Food, CFO, Saint Mary's Hospital, GERD, Investment, EFS, Surgeon, Nissen fundoplication, Learning, Vienna General Hospital, Patient, CET, Congress, FDA, ARB, NHS, AFS, Food and Drug Administration, Usability, IPAC, Certification, ISPOR, Health, Hospital, PMA, Hernia, Pharmaceutical industry, Medical device

The Interventional Procedures Advisory Committee (IPAC) has now started its review of the safety and efficacy of RefluxStop™.

Key Points: 
  • The Interventional Procedures Advisory Committee (IPAC) has now started its review of the safety and efficacy of RefluxStop™.
  • The IPAC review process is a key step for NHS hospitals to adopt our technology with strong international influence.
  • Implantica will hold a teleconference on 22 November 2023 at 15:00 (CET) with Peter Forsell (CEO), Andreas Öhrnberg (CFO), and Nicole Pehrsson (Chief Corporate Affairs Officer).
  • The information was submitted for publication, through the agency of the contact person set out above, at 2023-11-22 08:00 CET.

Implantica's RefluxStopTM, a promising new procedure for chronic acid reflux, offered for the first time in the NHS in UK

Retrieved on: 
화요일, 11월 21, 2023
Cough, Depression, Stomach, Kidney disease, Risk, Food, Patient, CET, Saint Mary's Hospital, University of York, NHS, St. Mary's, Trust, Certification, Catherine Disher, Consultant, GORD, Pain, Insomnia, Quality of life, Mary, mother of Jesus, Asthma, Hospital, Nursing, Health insurance

Four patients with GORD underwent the RefluxStop™ procedure in early September at St Mary's hospital, part of Imperial College Healthcare NHS Trust.

Key Points: 
  • Four patients with GORD underwent the RefluxStop™ procedure in early September at St Mary's hospital, part of Imperial College Healthcare NHS Trust.
  • All had minimally invasive, keyhole surgery, were quickly discharged from hospital and have made an excellent recovery.
  • Approximately 20% of the adult UK population have problems with severe acid reflux[1] or GORD.
  • We are pleased to announce that this landmark achievement of the first surgeries in NHS UK have now taken place.

Sentynl Therapeutics Announces Presentation of Study Evaluating the Efficacy and Safety of NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A at 2023 SSIEM Annual Symposium

Retrieved on: 
목요일, 9월 7, 2023
Seizure, Consultant, Infection, European Medicines Agency, Encephalopathy, Survival, Necrotizing enterocolitis, Genetic distance, Cox, Whole genome sequencing, Biochemistry, Molecular medicine, Ministry, Fosdenopterin, RSV, Patient, University of Cologne, Risk, Chemistry, Growth, Mortality, Saint Mary's Hospital, Hospital, Rare, Caregiver, Therapy, Death, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Molybdenum cofactor deficiency, Pneumonia, Food, Safety, Pharmaceutical industry, Metabolism, Health

SOLANA BEACH, Calif., Sept. 7, 2023 /PRNewswire/ -- Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases, announced that data evaluating NULIBRY® (fosdenopterin) for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A were presented at the 2023 Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Meeting on Aug. 30 in Jerusalem. NULIBRY is indicated to reduce the risk of mortality in patients with MoCD Type A, an ultra-rare, autosomal recessive, inborn error of metabolism causing sulfite-induced neurodegeneration and early death.

Key Points: 
  • NULIBRY is indicated to reduce the risk of mortality in patients with MoCD Type A, an ultra-rare, autosomal recessive, inborn error of metabolism causing sulfite-induced neurodegeneration and early death.
  • "Early treatment with fosdenopterin (NULIBRY) improves survival and neurodevelopmental outcomes, reducing burden on patients and caregivers."
  • Treatment with rcPMP/NULIBRY led to a normalization of MoCD Type A-associated urinary biomarker levels.
  • To further evaluate the safety and efficacy of NULIBRY, a post-approval non-interventional study is being initiated in Europe.

ENT Partners Opens 20th clinic location

Retrieved on: 
화요일, 8월 29, 2023
ENT, Patient, Partnership, St. Joseph's Hospital, Ear, Allergy, Hearing loss, Sleep, Mary, mother of Jesus, Doctor of Audiology, TK, Nose, Suite, Audiology, St. Francis Hospital, Diagnosis, Hospital, Saint Mary's Hospital, Health, Ascension, Nursing, Chicago metropolitan area, MD

MINNEAPOLIS, Aug. 29, 2023 /PRNewswire/ -- ENT Partners, LLC , a leading Physician Practice Management Company (PPMC) announced that Chicago ENT one of the largest ear, nose, and throat practices in Illinois, and part of the ENT Partners family of practices has opened its newest practice location at Ascension Saint Joseph Hospital in the Lakeview area of Chicago on August 29, 2023.

Key Points: 
  • MINNEAPOLIS, Aug. 29, 2023 /PRNewswire/ -- ENT Partners, LLC , a leading Physician Practice Management Company (PPMC) announced that Chicago ENT one of the largest ear, nose, and throat practices in Illinois, and part of the ENT Partners family of practices has opened its newest practice location at Ascension Saint Joseph Hospital in the Lakeview area of Chicago on August 29, 2023.
  • "We are delighted to announce the opening of our sixth office, where we proudly offer ENT services tailored to our patients' needs.
  • "Expanding our footprint and health-system relationships across the Chicagoland area is a great step for ENT Partners," said Jim Feinstein CEO of ENT Partners.
  • Patients may schedule appointments at Chicago ENT - Lakeview through their website, ChicagoENT.com , or by calling 773.296.5500.

Sempra Appoints Richard Mark to Board of Directors

Retrieved on: 
목요일, 8월 17, 2023
BMV, Public policy, Iowa State University, SAN, Tenet Healthcare, National Louis University, Hospital, Saint Mary's Hospital, NYSE, Safety, Renewable energy, Management, Ameren, Sempra

SAN DIEGO, Aug. 17, 2023 /PRNewswire/ -- Sempra (NYSE: SRE) (BMV: SRE) today announced that it has appointed Richard Mark to the company's board of directors effective Aug. 21, 2023.

Key Points: 
  • SAN DIEGO, Aug. 17, 2023 /PRNewswire/ -- Sempra (NYSE: SRE) (BMV: SRE) today announced that it has appointed Richard Mark to the company's board of directors effective Aug. 21, 2023.
  • Richard Mark is the former chairman and president of Ameren Illinois.
  • "Our board of directors embody a diverse set of skills, experiences and perspectives and offer important insights that help guide Sempra's success.
  • With the appointment of Mark, Sempra will have 10 directors with five having been newly elected since 2018, reflecting the company's commitment to continue growing and benefitting from fresh insights and perspectives.

MedStar Health Names Thomas J. Senker, FACHE, President of Two Hospitals

Retrieved on: 
수요일, 7월 12, 2023
MedStar Union Memorial Hospital, MedStar Good Samaritan Hospital, Heart, University, Bed, Elective surgery, Chambers, MedStar Montgomery Medical Center, Health, Spine, Multimedia, Geriatrics, Saint Mary's Hospital, MedStar Health, Teaching hospital, Sternberg Women's Board-a-Match Teams, Hospital, Sandy Spring Bank, Patient, Growth, General surgery, Nursing, Management

BALTIMORE, July 12, 2023 /PRNewswire/ -- MedStar Health has named Thomas "T.J." Senker, FACHE, president of MedStar Good Samaritan and MedStar Union Memorial Hospitals, and senior vice-president of MedStar Health, effective July 1. He replaces Bradley S. Chambers, who led the integration of the two hospitals in 2015 and maintained the dual presidency ever since, even after becoming MedStar Health's senior vice-president and regional chief operating officer for Baltimore, last year.

Key Points: 
  • Leadership at MedStar Good Samaritan and MedStar Union Memorial Hospitals, Effective July 1
    BALTIMORE, July 12, 2023 /PRNewswire/ -- MedStar Health has named Thomas "T.J." Senker, FACHE, president of MedStar Good Samaritan and MedStar Union Memorial Hospitals, and senior vice-president of MedStar Health, effective July 1.
  • "I am honored to continue with the mission of these separate, yet unified hospitals."
  • After 15 years as president at MedStar Union Memorial, and eight with MedStar Good Samaritan, passing the baton would require a high level of confidence in my successor.
  • The appointment means a return to Baltimore for the 47-year-old executive, who began his MedStar Health career as vice-president of operations at MedStar Good Samaritan Hospital in 2008.

Jury Finds Athens, Ga. Doctor Responsible for Death of Former Athens Musician and Business Owner, Returns $4.36 Million Verdict

Retrieved on: 
화요일, 2월 14, 2023
Perforation, Physician, Coffee, The Little Tigers, Pain, Saint Mary's Hospital, State court, Hospital, University, White Squall (film), Tiger, Squall, Cardiac catheterization, Heart, Mary, mother of Jesus, State court magistrate judge, Medical device, Psychology

ATHENS, Ga., Feb. 14, 2023 /PRNewswire/ -- On Feb. 8, 2023, a jury in the State Court of Clarke County in Athens, Ga. returned an $4.36 million verdict against Athens Heart Center, P.C.

Key Points: 
  • ATHENS, Ga., Feb. 14, 2023 /PRNewswire/ -- On Feb. 8, 2023, a jury in the State Court of Clarke County in Athens, Ga. returned an $4.36 million verdict against Athens Heart Center, P.C.
  • and Dr. Subodh Agrawal after a six-day trial focusing on the wrongful death of popular Athens musician and restaurant owner Juan Molina following a routine, elective diagnostic cardiac procedure.
  • Molina died on August 25, 2017 after undergoing a diagnostic cardiac catheterization at St. Mary's Hospital in Athens, Ga. that resulted in a fatal ventricle perforation.
  • The jury determined that Molina's death was due to medical malpractice on the part of Dr. Agrawal.

LumaBridge Welcomes Dr. Alexander Stojadinovic as Chief Medical Officer

Retrieved on: 
화요일, 11월 8, 2022
Surgical oncology, MBA, Memorial Sloan Kettering Cancer Center, Hospital, United States service academies, University, Institute, Uniformed Services University of the Health Sciences, Patient, SAN, Bon, Journal of Surgical Oncology, Journal, Program, FACS, Triple accreditation, Drug development, GlaxoSmithKline, MSKCC, Saint Mary's Hospital, Medicine, Maryland School, Walter Reed Army Medical Center, Clinical Medicine Insights: Oncology, Harvard Business School, Partnership, Master of Science, Science, Memorial, European Journal of Cancer, Research, CRO, Outline of health sciences, Health, Strategic planning, Pharmaceutical industry, Management, MD, Cancer, Pharmacy

SAN ANTONIO, Nov. 8, 2022 /PRNewswire/ -- LumaBridge (formerly known as Cancer Insight), a clinical research organization (CRO) dedicated to discovering, developing, and testing emerging biotechnologies related to cancer therapies, welcomes a new chief medical officer, Alexander Stojadinovic, MD, MBA, MSc, FACS.

Key Points: 
  • SAN ANTONIO, Nov. 8, 2022 /PRNewswire/ -- LumaBridge (formerly known as Cancer Insight), a clinical research organization (CRO) dedicated to discovering, developing, and testing emerging biotechnologies related to cancer therapies, welcomes a new chief medical officer, Alexander Stojadinovic, MD, MBA, MSc, FACS.
  • He brings to LumaBridge his extensive experience in strategic planning, program development, team building, operations, and research and development.
  • Dr. Stojadinovic has served as senior medical director in oncology clinical development at GlaxoSmithKline, as medical director of healthcare management services for Amerigroup Texas, and as a consulting surgical oncologist and healthcare executive.
  • "We are thrilled to welcome Alex to the team," said George E. Peoples, MD, FACS, founder, chief scientific officer, and executive chairman of LumaBridge.

Dennis Ohlrogge, MD, is being recognized by Continental Who's Who

Retrieved on: 
목요일, 7월 21, 2022
Saint Mary's Hospital, University, Family medicine, Medicine, American Board of Family Medicine, University of Minnesota Medical School, Retirement, Continental, American Board of Commissioners for Foreign Missions, Mayo Clinic Health System, Mary, mother of Jesus, Cancer, Hospital, MD, Patient, Golf, Medical degree, Saint Clare

A seasoned, board-certified physician, Dr. Ohlrogge began his illustrious career in medicine in 1982.

Key Points: 
  • A seasoned, board-certified physician, Dr. Ohlrogge began his illustrious career in medicine in 1982.
  • The doctor specialized in providing comprehensive medical treatment and preventative care to people of all ages during his career.
  • In pursuit of his career, Dr. Ohlrogge earned his Medical Degree from the University of Minnesota Medical School in 1979.
  • In his free time, Dr. Ohlrogge enjoys playing golf and spending time with his 28-year-old son.